Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Infectious Disease Reports
Published in: Current Infectious Disease Reports 5/2012

01-10-2012 | Sepsis (J Russell, Section Editor)

Cardiovascular Management of Septic Shock in 2012

Authors: Maria Cristina Vazquez Guillamet, Chanu Rhee, Andrew J. Patterson

Published in: Current Infectious Disease Reports | Issue 5/2012

Login to get access

Abstract

Septic shock is a major cause of morbidity and mortality throughout the world. Source control, antimicrobial therapy, early goal-directed fluid resuscitation, and infusion of vasoactive pharmaceuticals remain the cornerstones of treatment. However, the cardiovascular management of septic shock is evolving. Basic science and clinical researchers have identified novel drug targets and are testing the efficacy of new therapeutic agents. For example, prevention of microvascular leak during septic shock is the focus of active investigations and may soon provide considerable benefit to patients. Among the important topics that will be discussed in this review are the following: the role of vascular endothelial dysfunction in microvascular leak, the impact of cytokines upon structural and functional proteins within the endothelial barrier and within the heart, and the ability of selective vasopressin 1a receptor agonists to minimize tissue edema and improve hemodynamic status.
Literature
1.
Fernandes Jr CJ, Akamine N, Knobel E. Myocardial depression in sepsis. Shock. 2008;30 Suppl 1:14–7.PubMedCrossRef
2.
Zanotti-Cavazzoni SL, Hollenberg SM. Cardiac dysfunction in severe sepsis and septic shock. Curr Opin Crit Care. 2009;15:392–7.PubMedCrossRef
3.
4.
5.
Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001;345:1368–77.PubMedCrossRef
6.
7.
Parrillo JE. Septic shock–vasopressin, norepinephrine, and urgency. N Engl J Med. 2008;358:954–6.PubMedCrossRef
8.
Lee WL, Liles WC. Endothelial activation, dysfunction and permeability during severe infections. Curr Opin Hematol. 2011;18:191–6.PubMedCrossRef
9.
Mochizuki N. Vascular integrity mediated by vascular endothelial cadherin and regulated by sphingosine 1-phosphate and angiopoietin-1. Circ J. 2009;73:2183–91.PubMedCrossRef
10.
Hoang MV, Nagy JA, Senger DR. Active Rac1 improves pathologic VEGF neovessel architecture and reduces vascular leak: mechanistic similarities with angiopoietin-1. Blood. 2011;117:1751–60.PubMedCrossRef
11.
Hu H, Li X, Li Y, et al. Calpain-1 induces apoptosis in pulmonary microvascular endothelial cells under septic conditions. Microvasc Res. 2009;78:33–9.PubMedCrossRef
12.
Jonkam CC, Lange M, Traber DL, et al. Cardiovascular collapse and vascular permeability changes in an ovine model of methicillin-resistant Staphylococcus aureus sepsis. Shock. 2009;32:621–5.PubMedCrossRef
13.
Siner JM, Bhandari V, Engle KM, et al. Elevated serum angiopoietin 2 levels are associated with increased mortality in sepsis. Shock. 2009;31:348–53.PubMedCrossRef
14.
•• London NR, Zhu W, Bozza FA, et al.: Targeting Robo4-dependent Slit signaling to survive the cytokine storm in sepsis and influenza. Sci Transl Med. 2010;2:23ra19. This study offers a new interesting therapeutic target in the management of septic shock. The slit protein binds to the Robo-4 receptor on the endothelial cells and thus stabilizes the intercellular junctions. The net effect in animal models was decreased vascular leak and decreased mortality.
15.
Ye X, Ding J, Zhou X, et al. Divergent roles of endothelial NF-kappaB in multiple organ injury and bacterial clearance in mouse models of sepsis. J Exp Med. 2008;205:1303–15.PubMedCrossRef
16.
Zhou M, Wang P, Chaudry IH. Endothelial nitric oxide synthase is downregulated during hyperdynamic sepsis. Biochim Biophys Acta. 1997;1335:182–90.PubMedCrossRef
17.
• Ait-Oufella H, Maury E, Lehoux S, et al. The endothelium: physiological functions and role in microcirculatory failure during severe sepsis. Intensive Care Med. 2010;36:1286–98. Extensive and up-to-date review of the entdothelium and its functions focusing on changes that occur in sepsis.PubMedCrossRef
18.
Franco RF, de Jonge E, Dekkers PE, et al. The in vivo kinetics of tissue factor messenger RNA expression during human endotoxemia: relationship with activation of coagulation. Blood. 2000;96:554–9.PubMed
19.
Lupu C, Westmuckett AD, Peer G, et al. Tissue factor-dependent coagulation is preferentially up-regulated within arterial branching areas in a baboon model of Escherichia coli sepsis. Am J Pathol. 2005;167:1161–72.PubMedCrossRef
20.
Faust SN, Levin M, Harrison OB, et al. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med. 2001;345:408–16.PubMedCrossRef
21.
Sandset PM, Warn-Cramer BJ, Rao LV, et al. Depletion of extrinsic pathway inhibitor (EPI) sensitizes rabbits to disseminated intravascular coagulation induced with tissue factor: evidence supporting a physiologic role for EPI as a natural anticoagulant. Proc Natl Acad Sci USA. 1991;88:708–12.PubMedCrossRef
22.
Creasey AA, Chang AC, Feigen L, et al. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest. 1993;91:2850–60.PubMedCrossRef
23.
Mavrommatis AC, Theodoridis T, Economou M, et al. Activation of the fibrinolytic system and utilization of the coagulation inhibitors in sepsis: comparison with severe sepsis and septic shock. Intensive Care Med. 2001;27:1853–9.PubMedCrossRef
24.
Vieillard-Baron A, Caille V, Charron C, et al. Actual incidence of global left ventricular hypokinesia in adult septic shock. Crit Care Med. 2008;36:1701–6.PubMedCrossRef
25.
Parker MM, Shelhamer JH, Bacharach SL, et al. Profound but reversible myocardial depression in patients with septic shock. Ann Intern Med. 1984;100:483–90.PubMed
26.
Bouhemad B, Nicolas-Robin A, Arbelot C, et al. Isolated and reversible impairment of ventricular relaxation in patients with septic shock. Crit Care Med. 2008;36:766–74.PubMedCrossRef
27.
• Landesberg G, Gilon D, Meroz Y, et al. Diastolic dysfunction and mortality in severe sepsis and septic shock. Eur Heart J. 2012;33:895–903. Septic cardiomyopathy is a clinical entity that deserves future research. This was a large observational study using tissue Doppler imaging to assess cardiac function in patients with severe sepsis. It found that diastolic dysfunction had a significant impact on mortality.PubMedCrossRef
28.
Fernandes Jr CJ, Akamine N, Knobel E. Cardiac troponin: a new serum marker of myocardial injury in sepsis. Intensive Care Med. 1999;25:1165–8.PubMedCrossRef
29.
Mehta NJ, Khan IA, Gupta V, et al. Cardiac troponin I predicts myocardial dysfunction and adverse outcome in septic shock. Int J Cardiol. 2004;95:13–7.PubMedCrossRef
30.
Ammann P, Maggiorini M, Bertel O, et al. Troponin as a risk factor for mortality in critically ill patients without acute coronary syndromes. J Am Coll Cardiol. 2003;41:2004–9.PubMedCrossRef
31.
Rosjo H, Varpula M, Hagve TA, et al. Circulating high sensitivity troponin T in severe sepsis and septic shock: distribution, associated factors, and relation to outcome. Intensive Care Med. 2011;37:77–85.PubMedCrossRef
32.
Post F, Weilemann LS, Messow CM, et al. B-type natriuretic peptide as a marker for sepsis-induced myocardial depression in intensive care patients. Crit Care Med. 2008;36:3030–7.PubMedCrossRef
33.
Muller-Werdan U, Buerke M, Ebelt H, et al. Septic cardiomyopathy—a not yet discovered cardiomyopathy? Exp Clin Cardiol. 2006;11:226–36.PubMed
34.
Kumar A, Thota V, Dee L, et al. Tumor necrosis factor alpha and interleukin 1beta are responsible for in vitro myocardial cell depression induced by human septic shock serum. J Exp Med. 1996;183:949–58.PubMedCrossRef
35.
Boyd JH, Mathur S, Wang Y, et al. Toll-like receptor stimulation in cardiomyoctes decreases contractility and initiates an NF-kappaB dependent inflammatory response. Cardiovasc Res. 2006;72:384–93.PubMedCrossRef
36.
Boyd JH, Kan B, Roberts H, et al. S100A8 and S100A9 mediate endotoxin-induced cardiomyocyte dysfunction via the receptor for advanced glycation end products. Circ Res. 2008;102:1239–46.PubMedCrossRef
37.
Davani EY, Dorscheid DR, Lee CH, et al. Novel regulatory mechanism of cardiomyocyte contractility involving ICAM-1 and the cytoskeleton. Am J Physiol Heart Circ Physiol. 2004;287:H1013–22.PubMedCrossRef
38.
Davani EY, Boyd JH, Dorscheid DR, et al. Cardiac ICAM-1 mediates leukocyte-dependent decreased ventricular contractility in endotoxemic mice. Cardiovasc Res. 2006;72:134–42.PubMedCrossRef
39.
Balligand JL, Ungureanu D, Kelly RA, et al. Abnormal contractile function due to induction of nitric oxide synthesis in rat cardiac myocytes follows exposure to activated macrophage-conditioned medium. J Clin Invest. 1993;91:2314–9.PubMedCrossRef
40.
Brady AJ, Warren JB, Poole-Wilson PA, et al. Nitric oxide attenuates cardiac myocyte contraction. Am J Physiol. 1993;265:H176–82.PubMed
41.
Ullrich R, Scherrer-Crosbie M, Bloch KD, et al. Congenital deficiency of nitric oxide synthase 2 protects against endotoxin-induced myocardial dysfunction in mice. Circulation. 2000;102:1440–6.PubMedCrossRef
42.
Grandel U, Sibelius U, Schrickel J, et al. Biosynthesis of constitutive nitric oxide synthase-derived nitric oxide attenuates coronary vasoconstriction and myocardial depression in a model of septic heart failure induced by Staphylococcus aureus alpha-toxin. Crit Care Med. 2001;29:1–7.PubMedCrossRef
43.
Belcher E, Mitchell J, Evans T. Myocardial dysfunction in sepsis: no role for NO? Heart. 2002;87:507–9.PubMedCrossRef
44.
Annane D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA. 2002;288:862–71.PubMedCrossRef
45.
Shenker Y, Skatrud JB. Adrenal insufficiency in critically ill patients. Am J Respir Crit Care Med. 2001;163:1520–3.PubMed
46.
Annane D, Sebille V, Troche G, et al. A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. JAMA. 2000;283:1038–45.PubMedCrossRef
47.
Sonneville R, Guidoux C, Barrett L, et al. Vasopressin synthesis by the magnocellular neurons is different in the supraoptic nucleus and in the paraventricular nucleus in human and experimental septic shock. Brain Pathol. 2010;20:613–22.PubMedCrossRef
48.
Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006;34:1589–96.PubMedCrossRef
49.
Gaieski DF, Mikkelsen ME, Band RA, et al. Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department. Crit Care Med. 2010;38:1045–53.PubMedCrossRef
50.
Ibrahim EH, Sherman G, Ward S, et al. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest. 2000;118:146–55.PubMedCrossRef
51.
Kollef MH, Sherman G, Ward S, et al. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest. 1999;115:462–74.PubMedCrossRef
52.
Dellinger RP, Carlet JM, Masur H, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med. 2004;32:858–73.PubMedCrossRef
53.
Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med. 2008;36:296–327.PubMedCrossRef
54.
Balogh Z, Moore FA, Moore EE, et al. Secondary abdominal compartment syndrome: a potential threat for all trauma clinicians. Injury. 2007;38:272–9.PubMedCrossRef
55.
Coats TJ, Brazil E, Heron M, et al. Impairment of coagulation by commonly used resuscitation fluids in human volunteers. Emerg Med J. 2006;23:846–9.PubMedCrossRef
56.
57.
Wiedemann HP, Wheeler AP, Bernard GR, et al. Comparison of two fluid-management strategies in acute lung injury. N Engl J Med. 2006;354:2564–75.PubMedCrossRef
58.
Wheeler AP, Bernard GR, Thompson BT, et al. Pulmonary-artery versus central venous catheter to guide treatment of acute lung injury. N Engl J Med. 2006;354:2213–24.PubMedCrossRef
59.
Michard F, Teboul JL. Predicting fluid responsiveness in ICU patients: a critical analysis of the evidence. Chest. 2002;121:2000–8.PubMedCrossRef
60.
Barbier C, Loubieres Y, Schmit C, et al. Respiratory changes in inferior vena cava diameter are helpful in predicting fluid responsiveness in ventilated septic patients. Intensive Care Med. 2004;30:1740–6.PubMed
61.
Perel A. Automated assessment of fluid responsiveness in mechanically ventilated patients. Anesth Analg. 2008;106:1031–3.PubMedCrossRef
62.
Kaplan LJ, Kellum JA. Initial pH, base deficit, lactate, anion gap, strong ion difference, and strong ion gap predict outcome from major vascular injury. Crit Care Med. 2004;32:1120–4.PubMedCrossRef
63.
Zornow MH, Prough DS. Fluid management in patients with traumatic brain injury. New Horiz. 1995;3:488–98.PubMed
64.
65.
Vincent JL: Fluid resuscitation: colloids vs crystalloids. Acta Clin Belg Suppl. 2007;408-11.
66.
Jaskille A, Alam HB, Rhee P, et al.: D-lactate increases pulmonary apoptosis by restricting phosphorylation of bad and eNOS in a rat model of hemorrhagic shock. J Trauma. 2004;57:262-69; discussion 269-70.
67.
Ayuste EC, Chen H, Koustova E, et al. Hepatic and pulmonary apoptosis after hemorrhagic shock in swine can be reduced through modifications of conventional Ringer's solution. J Trauma. 2006;60:52–63.PubMedCrossRef
68.
Investigators SS. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med. 2004;350:2247–56.CrossRef
69.
Finfer S, McEvoy S, Bellomo R, et al. Impact of albumin compared to saline on organ function and mortality of patients with severe sepsis. Intensive Care Med. 2011;37:86–96.PubMedCrossRef
70.
McIntyre LA, Fergusson D, Cook DJ, et al. Resuscitating patients with early severe sepsis: a Canadian multicentre observational study. Can J Anaesth. 2007;54:790–8.PubMedCrossRef
71.
McIntyre L, Fergusson DA, Rowe B, et al. The PRECISE RCT: Evolution of an Early Septic Shock Fluid Resuscitation Trial. Transfus Med Rev. 2012.
72.
Mortelmans Y, Merckx E, van Nerom C, et al. Effect of an equal volume replacement with 500 mL 6% hydroxyethyl starch on the blood and plasma volume of healthy volunteers. Eur J Anaesthesiol. 1995;12:259–64.PubMed
73.
Nagy KK, Davis J, Duda J, et al. A comparison of pentastarch and lactated Ringer's solution in the resuscitation of patients with hemorrhagic shock. Circ Shock. 1993;40:289–94.PubMed
74.
Claes Y, Van Hemelrijck J, Van Gerven M, et al. Influence of hydroxyethyl starch on coagulation in patients during the perioperative period. Anesth Analg. 1992;75:24–30.PubMedCrossRef
75.
Brunkhorst FM, Engel C, Bloos F, et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med. 2008;358:125–39.PubMedCrossRef
76.
Sakr Y, Payen D, Reinhart K, et al. Effects of hydroxyethyl starch administration on renal function in critically ill patients. Br J Anaesth. 2007;98:216–24.PubMedCrossRef
77.
Perner A, Haase N, Guttormsen AB, et al. Hydroxyethyl Starch 130/0.4 versus Ringer's Acetate in Severe Sepsis. N Engl J Med. 2012.
78.
Shander A, Javidroozi M, Ozawa S, et al. What is really dangerous: anaemia or transfusion? Br J Anaesth. 2011;107 Suppl 1:i41–59.PubMedCrossRef
79.
Hébert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. N Engl J Med. 1999;340:409–17.PubMedCrossRef
80.
Levi M, Toh CH, Thachil J, et al. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. Br J Haematol. 2009;145:24–33.PubMedCrossRef
81.
Wallis JP. Editorial I: transfusion-related acute lung injury (TRALI)—under-diagnosed and under-reported. Br J Anaesth. 2003;90:573–6.PubMedCrossRef
82.
Toy P, Gajic O, Bacchetti P, et al. Transfusion-related acute lung injury: incidence and risk factors. Blood. 2012;119:1757–67.PubMedCrossRef
83.
De Backer D, Creteur J, Silva E, et al. Effects of dopamine, norepinephrine, and epinephrine on the splanchnic circulation in septic shock: which is best? Crit Care Med. 2003;31:1659–67.PubMedCrossRef
84.
De Backer D, Biston P, Devriendt J, et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med. 2010;362:779–89.PubMedCrossRef
85.
86.
Dunser MW, Mayr AJ, Ulmer H, et al. Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation. 2003;107:2313–9.PubMedCrossRef
87.
Traber D. Selective V1a receptor agonists in experimental septic shock. Crit Care. 2007;11:P51.CrossRef
88.
•• Rehberg S, Ertmer C, Vincent JL, et al. Role of selective V1a receptor agonism in ovine septic shock. Crit Care Med. 2011;39:119–25. This study opens the possibility to new therapuetic targets in septic shock management: vasopressin analogues that are V1 receptor selective. In a fecal peritonitis-induced septic shock animal model an experimental V1 agonist showed better hemodynamics, vascular leak and mortality when compared to standard treatment (vasopressin and single norepinephrine infusion).PubMedCrossRef
89.
Annane D, Vignon P, Renault A, et al. Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial. Lancet. 2007;370:676–84.PubMedCrossRef
90.
Leone M, Martin C. Vasopressor use in septic shock: an update. Curr Opin Anaesthesiol. 2008;141-7.
91.
Antonopoulos A, Nikolopoulos D, Georgiou EK, et al. Blood pressure elevation after phenylephrine infusion may adversely affect myocardial perfusion in patients with coronary artery disease. Int J Cardiol. 2002;84:201–9.PubMedCrossRef
92.
Morelli A, Ertmer C, Rehberg S, et al. Phenylephrine versus norepinephrine for initial hemodynamic support of patients with septic shock: a randomized, controlled trial. Crit Care. 2008;12:R143.PubMedCrossRef
93.
Beale RJ, Hollenberg SM, Vincent JL, et al. Vasopressor and inotropic support in septic shock: an evidence-based review. Crit Care Med. 2004;32:S455–65.PubMedCrossRef
94.
• Annane D, Bellissant E, Bollaert PE, et al. Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review. JAMA. 2009;301:2362–75. After contradictory randomized trials, this meta-analysis was published showing that low-dose treatment with corticosteroids may be beneficial in severe sepsis and septic shock. The right answer for use of steroids is still a matter of debate.PubMedCrossRef
95.
Dellinger RP. Steroid therapy of septic shock: the decision is in the eye of the beholder. Crit Care Med. 2008;36:1987–9.PubMedCrossRef
Metadata
Title
Cardiovascular Management of Septic Shock in 2012
Authors
Maria Cristina Vazquez Guillamet
Chanu Rhee
Andrew J. Patterson
Publication date
01-10-2012
Publisher
Current Science Inc.
Published in
Current Infectious Disease Reports / Issue 5/2012
Print ISSN: 1523-3847
Electronic ISSN: 1534-3146
DOI
https://doi.org/10.1007/s11908-012-0279-z

Other articles of this Issue 5/2012

Current Infectious Disease Reports 5/2012 Go to the issue

Skin, Soft Tissue, Bone and Joint Infections (N Safdar, Section Editor)

Chronic Osteomyelitis

Sepsis (J Russell, Section Editor)

Immune Aspects of Sepsis and Hope for New Therapeutics

Skin, Soft Tissue, Bone and Joint Infections (N Safdar, Section Editor)

Prevention of Surgical Site Infections in Bone and Joint Procedures

Skin, Soft Tissue, Bone, and Joint Infections (N Safdar, Section Editor)

Septic Arthritis in the Native Joint

Sepsis (J Russell, Section Editor)

Management of Acute Renal Dysfunction in Sepsis

Sepsis (J Russell, Section Editor)

Pediatric Sepsis: Preparing for the Future Against a Global Scourge
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits